TrialJournal of clinical pharmacology2026

First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Muscle-Specific Kinase Agonist Adimanebart (ARGX-119).

Tonke van Bragt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.